Browsing by Author Marx, Gavin

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 22  next >
Issue DateTitleAuthor(s)Citation
2016The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trialsChan, David; Clarke, Stephen; Khasraw, Mustafa; Lee, Adrian; Li, Bob; Marx, Gavin; Pavlakis, Nick; Barnes, Tristan; Drilon, Alexander D.; Kris, Mark G.; Naidoo, Jarushka; Rudin, Charles M.; Northern Clinical School: Medicine; Northern Clinical School: Kolling Institute; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; Central Clinical School: Pathology; SAHCS: Medicine; Northern Clinical School: MedicineThe addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials, Lung Cancer, vol.102, N/A, 2016,pp 21-27
2014Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancerBoyer, Michael; Gurney, Howard; Horvath, Lisa; Mahon, Kate; Marx, Gavin; Pavlakis, Nick; Stockler, Martin; Castillo, Lesley; Chiam, K; Clark, Susan J.; Daly, R; Lee, B Y; Lin, H-M; Mallesara, G; Nguyen, Q; Swarbrick, A.; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; School of Public Health: Public Health; Medicine; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreCirculating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer, British Journal of Cancer, vol.110, 10, 2014,pp 2462-2471
2015Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerBoyer, Michael; Horvath, Lisa; Mahon, Kate; Marx, Gavin; Pavlakis, Nick; Stockler, Martin; Breit, Samuel; Brown, David; Castillo, Lesley; Chatfield, Mark; Chiam, K; Daly, R; Henshall, Susan; Lee, B Y; Lee-Ng, K K Michelle; Lin, H-M; Molloy, Mark; Central Clinical School: Medicine; Central Clinical School: Medicine; School of Public Health: Public Health; Medicine; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreCytokine profiling of docetaxel-resistant castration-resistant prostate cancer, British Journal of Cancer, vol.112, 8, 2015,pp 1340-1348
2013Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostrate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling TimeMarx, Gavin; Damiao, Ronaldo; et al, Various; Fizazi, Karim; Miller, Kurt; Oudard, Stephanie; Saad, Fred; Shore, Neal; Sieber, Paul; Smith, Matthew; Tombal, Bertrand; Van Veldhuizen, Peter; MedicineDenosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostrate Cancer: Exploratory Analysis by Baseline Prostate-Specific Antigen Doubling Time, Journal of Clinical Oncology, vol.31, 30, 2013,pp 3800-3806
2017A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancerGurney, Howard; Horvath, Lisa; Hoy, Andrew; Marx, Gavin; Stockler, Martin; Briscoe, Karen; Daly, Roger; Lin, Hui-Ming; Mahon, Kate; Mallesara, Girish; Meikle, Peter; Mundra, Piyushkumar; Parton, Robert G.; Spielman, Calan; Weir, Jacquelyn; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; School of Medical Sciences: Physiology; SAHCS: Medicine; NH&MRC Clinical Trials CentreA distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer, International Journal of Cancer, vol.141, 10, 2017,pp 2112-2120
2017Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysisMarx, Gavin; Bergin, A.R.T.; de Souza, P; Hovey, E; Lloyd, A; Parente, P; Rapke, T; SAHCS: MedicineDocetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis, Supportive Care in Cancer, vol.25, 9, 2017,pp 2871-2879
2017Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic reviewMarx, Gavin; Pulvers, Jeremy; SAHCS: Medicine; AnaesthesiaFactors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review, Asia-Pacific Journal of Clinical Oncology, vol.13, 6, 2017,pp 345-355
2006Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.Marx, Gavin; Yip, Desmond; Cheong, K.; Chrystal, K.; Galani, E.; Gallagher, C.; Harper, P. G.; Lofts, F.; Steer, Christopher B.; Strickland, A. H.; Thomas, H.; Centre Regional Ed - Orange; MedicineGemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study., Gynecologic oncology, vol.103,(2),2006,pp 439-445
2015Geriatric assessment of older patients with cancer in Australia-A multicentre auditMarx, Gavin; Tattersall, Martin; Della Fiorentina, Stephen; Dunlop, Tracey; et al, Various; Hovey, Elizabeth; Joshi, Sachin; Lakhanpal, Roopa; Liew, Sem; Mileshkin, Linda; Venkateswaran, Lakshmi; Yip, Desmond; Yoong, Jaclyn; Medicine; Central Clinical School: MedicineGeriatric assessment of older patients with cancer in Australia-A multicentre audit, Journal of Geriatric Oncology, vol.6, 3, 2015,pp 185-193
2009Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.Boyer, Michael; Pavlakis, Nick; Stockler, Martin; Breit, Samuel N; Brown, David A.; Henshall, Susan M.; Horvath, L G; Kaplan, Warren; Lee, Brian; Marx, Gavin; Molloy, Mark; Sutherland, Robert L.; Zhao, Liangli; Central Clinical School: Medicine; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreIdentification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling., Cancer Research, vol.69, 19,pp 7696-7703
2014Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancerBoyer, Michael; Gurney, Howard; Horvath, Lisa; Mahon, Kate; Marx, Gavin; Stockler, Martin; Castillo, Lesley; Chatfield, Mark; Clark, Susan J.; Devaney, James; Mallesara, G; Molloy, Peter; Paul, Cheryl; Qu, W; Wykes, R J; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; School of Public Health: Public Health; Medicine; School of Public Health: NH&MRC Clinical Trials CentreMethylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer, British Journal of Cancer, vol.111, 9, 2014,pp 1802-1809
2010Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancerPavlakis, Nick; Begbie, Stephen; Boyce, Adam; De Souza, P; Harvie, Rozelle; Khasraw, M; Lim, V; Marx, Gavin; McCowatt, S; Parnis, F; Underhill, Craig; Northern Clinical School: MedicineMulticentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer, Annals of Oncology, vol.21, 6,pp 1302-1307
2015Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancerChan, David; Marx, Gavin; Crumbaker, Megan A; McLachlan, Jennifer; Northern Clinical School: Medicine; MedicineNeutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer, Cancer Treatment Communications, vol.4, N/A, 2015,pp 81-85
2005Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experienceMarx, Gavin; Goldstein, David; Taylor, J.; Centre Regional Ed - OrangeOutpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience, Internal Medicine Journal 2005, vol.35,(1),2005,pp 34-38
2016Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastasesMarx, Gavin; Body, Jean-Jacques; Brown, Janet; Cleeland, Charles; Damyanov, Danail; Egerdie, Blair; et al, Various; Fallowfield, L. J.; Palazzo, Felipe Salvador; Patrick, Donald; Stopeck, Alison; von Moos, Roger; SAHCS: MedicinePain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases, Supportive Care in Cancer, vol.24, 3, 2016,pp 1327-1337
2013Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acidMarx, Gavin; Body, Jean-Jacques; Brown, Janet; Cleeland, Charles; Damyanov, Danail; Egerdie, Blair; et al, Various; Fallowfield, L. J.; Patrick, Donald; Stopeck, Alison; von Moos, Roger; MedicinePain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid, Supportive Care in Cancer, vol.21, 12, 2013,pp 3497-3507
2017Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancerHorvath, Lisa; Marx, Gavin; Stockler, Martin; Bastick, Patricia; Briscoe, Karen; Gurney, H; Lin, H; Mahon, Kate; Mallesara, Girish; Spielman, Calan; Swarbrick, A; Central Clinical School: Medicine; SAHCS: Medicine; NH&MRC Clinical Trials CentrePhase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer, British Journal of Cancer, vol.116, 8, 2017,pp 1002-1011
2012The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabineClarke, Stephen; Cullen, Martin; Davey, Ross; Harvie, Rozelle; Kerestes, Zoltan; Marx, Gavin; Pavlakis, Nick; Taylor, Robyn; Abraham, R.; Kao, Steven; Paturi, Florian; Northern Clinical School: Kolling Institute; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Physics; Northern Clinical School: Kolling Institute; Medicine; Northern Clinical School: Medicine; Northern Clinical School: MedicineThe predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine, Lung Cancer, vol.75, 2, 2012,pp 248-254
2013Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancerGurney, Howard; Marx, Gavin; Patel, Manish; Won, Andy; de Souza, Paul; Western Clinical School: Medicine (Westmead); Medicine; Western Clinical School: Surgery; MedicinePrimary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer, BJU International, vol.112, 4, 2013,pp E250-E255
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838